Genprex, Inc. (NASDAQ:GNPX) Sees Large Decline in Short Interest

Genprex, Inc. (NASDAQ:GNPX) was the recipient of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 277,400 shares, a decrease of 16.8% from the March 15th total of 333,600 shares. Based on an average daily volume of 3,800,000 shares, the short-interest ratio is presently 0.1 days. Currently, 1.2% of the company’s stock are sold short.

Institutional Investors Weigh In On Genprex

An institutional investor recently raised its position in Genprex stock. Geode Capital Management LLC grew its holdings in shares of Genprex, Inc. (NASDAQ:GNPX) by 368.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 76,045 shares of the company’s stock after acquiring an additional 59,798 shares during the quarter. Geode Capital Management LLC owned 0.89% of Genprex worth $65,000 at the end of the most recent quarter. 14.05% of the stock is currently owned by hedge funds and other institutional investors.

Genprex Stock Performance

NASDAQ GNPX traded down $0.02 on Monday, hitting $0.23. 427,508 shares of the stock were exchanged, compared to its average volume of 3,454,850. Genprex has a 52 week low of $0.22 and a 52 week high of $4.09. The business’s fifty day moving average is $0.34 and its 200 day moving average is $0.80.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.